

CITATION REPORT

List of articles citing

Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease

DOI: 10.1111/dom.12666

Diabetes, Obesity and Metabolism, 2016, 18, 766-74.

Source: <https://exaly.com/paper-pdf/63396790/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
20	Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus. <i>Journal of Diabetes Research</i> , 2016 , 2016, 5347262	3.9	17
19	Herzinsuffizienz bei Diabetes vorbeugen und entgegenwirken. <i>Info Diabetologie</i> , 2016 , 10, 37-47	0	
18	Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 517-527	4	4
17	A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 763-772	3.8	11
16	Durability of response to dapagliflozin: a review of long-term efficacy and safety. <i>Current Medical Research and Opinion</i> , 2017 , 33, 1685-1696	2.5	9
15	Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus. <i>Cureus</i> , 2017 , 9, e1751	1.2	4
14	Sodium-Glucose Cotransporter-2 Inhibition in Type 2 Diabetes Mellitus: A Review of Large-Scale Cardiovascular Outcome Studies and Possible Mechanisms of Benefit. <i>Cardiology in Review</i> , 2018 , 26, 312-320	3.2	4
13	Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 458-462	6.7	145
12	Pharmacotherapy of type 2 diabetes: An update. <i>Metabolism: Clinical and Experimental</i> , 2018 , 78, 13-42	12.7	103
11	Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis. <i>BMJ Open</i> , 2019 , 9, e030596	3	7
10	Dapagliflozin: A Review in Type 2 Diabetes. <i>Drugs</i> , 2019 , 79, 1135-1146	12.1	37
9	Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus. <i>Chronic Diseases and Translational Medicine</i> , 2019 , 5, 25-36	3.9	3
8	Effects of Dapagliflozin Adjunct to Insulin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized, Controlled, Open-Labelled Trial. <i>BioMed Research International</i> , 2021 , 2021, 6618257	3	0
7	Role of Folic Acid Drugs in the Treatment with Antithrombotic and Anticoagulant Drugs for Patients with Cardiovascular Diseases Based on the Analysis of Virtual Reality Medical Data. <i>Journal of Healthcare Engineering</i> , 2021 , 2021, 9914787	3.7	0
6	Cardiovascular Effects of Sodium Glucose Co-transporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus. <i>Indian Journal of Endocrinology and Metabolism</i> , 2019 , 23, 150-158	1.7	1
5	Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021 ,	6.7	3
4	Empagliflozin in patient with heart failure and type 2 diabetes mellitus: new possibilities for drug therapy. <i>Medical Alphabet</i> , 2021 , 1, 8-12	0.3	

3	Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan. <i>PeerJ</i> , 2020 , 8, e9998	3.1	○
2	Effects of dapagliflozin in the progression of atherosclerosis in patients with type 2 diabetes: a meta-analysis of randomized controlled trials.. <i>Diabetology and Metabolic Syndrome</i> , 2022 , 14, 41	5.6	○
1	Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials.. <i>Therapeutic Advances in Chronic Disease</i> , 2022 , 13, 20406223221083509	4.9	○